Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE: JCARH125 in R/R Multiple Myeloma
NCT03430011Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2018
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of orvacabtagene autoleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Started Feb 2018; status: completed.
02
Drugs
orvacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03430011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430011.